Principal Investigator
Raphael Yechieli
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20250664
Clinical Trial Summary
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Thoracic Oncology
Contact Information
Phone Number
305-243-2647